SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-17-008320
Filing Date
2017-11-07
Accepted
2017-11-07 08:01:18
Documents
71
Period of Report
2017-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q acrs-20170930x10q.htm 10-Q 1656131
2 EX-2.1 acrs-20170930ex21d9ed579.htm EX-2.1 1172995
3 EX-10.1 acrs-20170930ex101db6106.htm EX-10.1 55594
4 EX-31.1 acrs-20170930ex311cabc54.htm EX-31.1 17142
5 EX-31.2 acrs-20170930ex312b4f359.htm EX-31.2 17128
6 EX-32.1 acrs-20170930ex321b9d951.htm EX-32.1 10675
7 GRAPHIC acrs20170930ex101db6106001.jpg GRAPHIC 75768
  Complete submission text file 0001558370-17-008320.txt   8245158

Data Files

Seq Description Document Type Size
8 EX-101.INS acrs-20170930.xml EX-101.INS 1646163
9 EX-101.SCH acrs-20170930.xsd EX-101.SCH 43320
10 EX-101.CAL acrs-20170930_cal.xml EX-101.CAL 57740
11 EX-101.DEF acrs-20170930_def.xml EX-101.DEF 142980
12 EX-101.LAB acrs-20170930_lab.xml EX-101.LAB 462868
13 EX-101.PRE acrs-20170930_pre.xml EX-101.PRE 315241
Mailing Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355
Business Address SUITE 400, 101 LINDENWOOD DRIVE MALVERN PA 19355 484-321-5554
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

IRS No.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37581 | Film No.: 171181156
SIC: 2834 Pharmaceutical Preparations